Skip to content

GSK Acquires Global Rights to Chinese Cancer Drug in $750 Million Deal

British pharmaceutical giant GSK buys full global rights to a multiple myeloma treatment from Chengdu-based Chimagen Biosciences.

2 publishers · 2 articles · first seen 15 Sept 2026 · updated 2h ago

Sources

Every article we clustered into this story. Headlines link to the publisher.

GSK licenses Chinese firm’s cancer drug in US$750 million deal South China Morning Post 2h ago
STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more STAT 14h ago

In this story

GSK
Chimagen Biosciences